Harnessing adipogenesis to prevent obesity

Adipocyte. 2019 Dec;8(1):98-104. doi: 10.1080/21623945.2019.1583037. Epub 2019 Mar 8.

Abstract

Obesity and associated metabolic complications, including diabetes, cardiovascular and hepatic diseases, and certain types of cancers, create a major socioeconomic burden. Obesity is characterized by excessive expansion of white adipose tissue resulting from increased adipocyte size, and enhanced adipocyte precursor cells proliferation and differentiation into mature adipocytes, a process well-defined as adipogenesis. Efforts to develop therapeutically potent strategies to circumvent obesity are impacted by our limited understanding of molecular mechanisms regulating adipogenesis. In this review, we discuss recently discovered molecular mechanisms restraining adipogenesis. In this perspective, the discoveries of white adipose tissue endogenous adipogenesis-regulatory cells (Aregs) that negatively regulate adipocyte differentiation, platelet-derived growth factor receptor isoform α (PDGFRα) activation and downstream signaling that hinder adipocyte precursors differentiation, and a group of obesity-associated non-coding RNAs (ncRNAs) that regulate adipogenesis open up promising therapeutic avenues to prevent and/or treat obesity.

Keywords: Adipocyte precursor cells; Aregs; PDGFRα; adipocyte; adipogenesis; lncRNA; miRNA; obesity; white adipose tissue.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adipocytes, White / metabolism
  • Adipogenesis / physiology*
  • Adipose Tissue / metabolism
  • Adipose Tissue, White / metabolism
  • Animals
  • Cell Differentiation / physiology
  • Humans
  • MicroRNAs / genetics
  • Obesity / metabolism*
  • Obesity / prevention & control*
  • RNA, Long Noncoding / genetics
  • Receptor, Platelet-Derived Growth Factor alpha / metabolism
  • Signal Transduction

Substances

  • MicroRNAs
  • RNA, Long Noncoding
  • Receptor, Platelet-Derived Growth Factor alpha

Grants and funding

N.H. is supported by a studentship from the Fonds de recherche du Québec-Santé (FRQS). L.L. is funded by Zavalkoff Foundation grant.